Clinical Trial Update: Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing whether suvorexant (MK-4305) reduces the incidence of delirium in Japanese individuals at high risk; results and safety data were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delirium

Drugs mentioned

• Suvorexant (MK-4305) (suvorexant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Delirium | Phase 3 | Status: COMPLETED | Results posted: 2024-05-20